[
  {
    "ts": null,
    "headline": "GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive",
    "summary": "Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the drug.",
    "url": "https://finnhub.io/api/news?id=164329f7dec41ecf2bd4db43d8d0bb9078739234f2373c6ec2d0a86bd1b96e58",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741806000,
      "headline": "GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive",
      "id": 133185358,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the drug.",
      "url": "https://finnhub.io/api/news?id=164329f7dec41ecf2bd4db43d8d0bb9078739234f2373c6ec2d0a86bd1b96e58"
    }
  },
  {
    "ts": null,
    "headline": "Analyst Says Gilead Sciences (GILD) is a ‘Big Liquid’ Stock You Should Pay Attention To",
    "summary": "We recently published a list of Top 10 Stocks Wall Street is Discussing. In this article, we are going to take a look at where Gilead Sciences Inc (NASDAQ:GILD) stands against other top stocks Wall Street is discussing. Bill Strazzullo, Bell Curve Trading chief market strategist, said in a latest program on CNBC that the […]",
    "url": "https://finnhub.io/api/news?id=c714696a3d3c233409b58ad0a6d19472a87edef1e6acdc88ababbc566cb6bd3c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741803386,
      "headline": "Analyst Says Gilead Sciences (GILD) is a ‘Big Liquid’ Stock You Should Pay Attention To",
      "id": 133185359,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "We recently published a list of Top 10 Stocks Wall Street is Discussing. In this article, we are going to take a look at where Gilead Sciences Inc (NASDAQ:GILD) stands against other top stocks Wall Street is discussing. Bill Strazzullo, Bell Curve Trading chief market strategist, said in a latest program on CNBC that the […]",
      "url": "https://finnhub.io/api/news?id=c714696a3d3c233409b58ad0a6d19472a87edef1e6acdc88ababbc566cb6bd3c"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data",
    "summary": "Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This upward trajectory coincides with positive developments in its HIV treatment portfolio, highlighted by successful data presentations at CROI 2025. The approval of lenacapavir for multi-drug resistant HIV and its promising trial results for once-yearly PrEP injections in significant publications emphasized Gilead's innovative edge. Coupled with robust earnings in Q4 2024,...",
    "url": "https://finnhub.io/api/news?id=58de4e1d2f634c0e401facb3c3e8545123fec00785e2ea86f5f08715063f6be1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741799824,
      "headline": "Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data",
      "id": 133185360,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This upward trajectory coincides with positive developments in its HIV treatment portfolio, highlighted by successful data presentations at CROI 2025. The approval of lenacapavir for multi-drug resistant HIV and its promising trial results for once-yearly PrEP injections in significant publications emphasized Gilead's innovative edge. Coupled with robust earnings in Q4 2024,...",
      "url": "https://finnhub.io/api/news?id=58de4e1d2f634c0e401facb3c3e8545123fec00785e2ea86f5f08715063f6be1"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Presents New HIV Treatment And Cure Research Data",
    "summary": "On Wednesday, Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). ALLIANCE is an ongoing Phase 3 study evaluating Biktarvy versus dolutegravir 50 mg (DTG) + emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg, F/TDF, DTG+F/TDF, in adults with HIV-1/HBV coinfection initiating treatment. Previously reported results demonstrated the efficacy of both antiretroviral regimens.",
    "url": "https://finnhub.io/api/news?id=3954db55b1b2fa236ae03fb1b560a682214b8ff209b662b85e5fcb1ea4727e75",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741798525,
      "headline": "Gilead Presents New HIV Treatment And Cure Research Data",
      "id": 133185361,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "On Wednesday, Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). ALLIANCE is an ongoing Phase 3 study evaluating Biktarvy versus dolutegravir 50 mg (DTG) + emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg, F/TDF, DTG+F/TDF, in adults with HIV-1/HBV coinfection initiating treatment. Previously reported results demonstrated the efficacy of both antiretroviral regimens.",
      "url": "https://finnhub.io/api/news?id=3954db55b1b2fa236ae03fb1b560a682214b8ff209b662b85e5fcb1ea4727e75"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Exelon, Gilead Sciences, Plains All American Pipeline, Sportradar and Cintas",
    "summary": "Exelon, Gilead Sciences, Plains All American Pipeline, Sportradar and Cintas are part of the Zacks top Analyst Blog",
    "url": "https://finnhub.io/api/news?id=7393b5a647ebcba634b440a3bc4d5f6562db57eb310d637af5fd4f9f47370be8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741785840,
      "headline": "The Zacks Analyst Blog Highlights Exelon, Gilead Sciences, Plains All American Pipeline, Sportradar and Cintas",
      "id": 133185362,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Exelon, Gilead Sciences, Plains All American Pipeline, Sportradar and Cintas are part of the Zacks top Analyst Blog",
      "url": "https://finnhub.io/api/news?id=7393b5a647ebcba634b440a3bc4d5f6562db57eb310d637af5fd4f9f47370be8"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option",
    "summary": "FOSTER CITY, Calif., March 12, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). The new findings reflect a transformative portfolio and a rapidly advancing forward-looking pipeline focused on expanding choices and enhancing outcomes for those with HIV, while continuing to reach towards",
    "url": "https://finnhub.io/api/news?id=91c2f966381d25501327d6a435f3e526f48a23eaf410f90f479e5a3cb720e7ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741782600,
      "headline": "Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option",
      "id": 133185363,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., March 12, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). The new findings reflect a transformative portfolio and a rapidly advancing forward-looking pipeline focused on expanding choices and enhancing outcomes for those with HIV, while continuing to reach towards",
      "url": "https://finnhub.io/api/news?id=91c2f966381d25501327d6a435f3e526f48a23eaf410f90f479e5a3cb720e7ce"
    }
  },
  {
    "ts": null,
    "headline": "Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I success",
    "summary": "The company has already seen massive success with a twice-yearly version of lenacapavir PrEP for HIV.",
    "url": "https://finnhub.io/api/news?id=c7d3156563c49292c85b417646fde7e5c1112df6a486158a167f145ed51a92a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741782221,
      "headline": "Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I success",
      "id": 133185364,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The company has already seen massive success with a twice-yearly version of lenacapavir PrEP for HIV.",
      "url": "https://finnhub.io/api/news?id=c7d3156563c49292c85b417646fde7e5c1112df6a486158a167f145ed51a92a0"
    }
  },
  {
    "ts": null,
    "headline": "First Clinical Data for Gilead's Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet",
    "summary": "FOSTER CITY - Gilead Sciences, Inc. today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company's injectable HIV-1...",
    "url": "https://finnhub.io/api/news?id=51fc684a503324f825cc8ce1cce9544e25abd03aaf47898d7926f23a149faa69",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741782146,
      "headline": "First Clinical Data for Gilead's Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet",
      "id": 133153092,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "FOSTER CITY - Gilead Sciences, Inc. today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company's injectable HIV-1...",
      "url": "https://finnhub.io/api/news?id=51fc684a503324f825cc8ce1cce9544e25abd03aaf47898d7926f23a149faa69"
    }
  }
]